Financial Performance - The company reported a significant loss due to the removal of its main product, Nerve Growth Factor injection, from the national medical insurance catalog, leading to a decline in sales[5]. - The company's operating revenue for 2020 was ¥524,123,427.37, a decrease of 15.49% compared to ¥620,163,188.70 in 2019[25]. - The net profit attributable to shareholders in 2020 was -¥25,025,702.16, representing a decline of 139.70% from ¥63,035,065.41 in 2019[25]. - The net cash flow from operating activities was -¥19,703,010.29 in 2020, down 131.26% from ¥63,027,543.20 in 2019[25]. - The total income of 17,171,208.03 in the current period, a decrease from 27,950,105.56 in the previous year, representing a decline of approximately 38.5%[32]. - The company reported a quarterly operating revenue of ¥175,529,048.11 in Q4 2020, showing a sequential increase from previous quarters[28]. - The company incurred a net loss of -¥14,499,253.88 in Q4 2020, following losses in the previous quarters[28]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as reflected in its financial performance[25]. Research and Development - R&D expenses increased by CNY 23.47 million compared to 2019, with R&D costs accounting for 16.43% of revenue, up from 10.10% in 2019[5]. - The company is developing a new drug, CPT, which has completed data lock and unblinding for its Phase III clinical trial, with results meeting expectations[9]. - The company plans to submit a New Drug Application (NDA) for CPT, pending regulatory review and approval processes[10]. - The company has a strong focus on R&D, with its main product "Jinlujie" being the world's first commercialized nerve growth factor new drug, launched in 2003[40]. - The company is advancing multiple projects, including the CPT project, which has completed Phase III clinical trials and is preparing for NDA submission[73]. - The CPT project has received significant funding and has multiple invention patents granted in 17 countries and regions[73]. - The company’s R&D services cover various therapeutic areas, including cardiovascular, respiratory, digestive, and endocrine systems[36]. - The company has established a comprehensive drug development service from R&D to clinical and production stages, enhancing its service offerings[36]. Market and Product Development - The company is focused on expanding its market presence with new products, particularly CPT, which could enhance its competitiveness if included in the medical insurance catalog[8]. - The company aims to increase the proportion of self-developed products through independent research and development of small molecule chemical drugs with good market prospects[58]. - The company is focusing on expanding its product offerings in the neurology and oncology fields, with a focus on innovative drug development[67]. - The company has established a comprehensive sales service network, collaborating with major distributors like Sinopharm and China Resources[67]. - The company has launched online promotional activities for its NGF product and conducted charitable drug donation campaigns to support patients during the pandemic[76]. Assets and Investments - The total assets at the end of 2020 were ¥2,186,566,003.25, an increase of 0.79% from ¥2,169,508,822.12 at the end of 2019[25]. - The net assets attributable to shareholders decreased by 2.49% to ¥1,708,652,006.75 at the end of 2020 from ¥1,752,293,190.99 at the end of 2019[25]. - The company's fixed assets increased by 28.27% compared to the previous year, amounting to ¥59,169,240.07, primarily due to construction projects and equipment purchases[63]. - Intangible assets grew by 48.92%, totaling ¥31,207,073.52, mainly from the increase in land use rights[63]. - The company has a total of RMB 479,569,950.00 in financial assets, with a fair value change of RMB 2,648,143.84[107]. Corporate Governance and Compliance - The company has not experienced any major litigation or arbitration matters during the reporting period[142]. - There were no significant penalties or rectification measures during the reporting period[143]. - The company has not engaged in any significant related party transactions during the reporting period[145]. - The company has established a dedicated bank account for managing the raised funds, ensuring proper oversight and usage[112]. - The company has committed a total investment of CNY 79,747.59 million, with a cumulative investment of CNY 42,599.49 million, achieving 53.41% of the planned investment[115]. Strategic Focus and Future Plans - The company is committed to becoming China's leading innovative drug enterprise, focusing on patient service and continuous innovation[127]. - The company plans to focus on the development of biopharmaceuticals, small molecule CRO, CDMO, and high-end raw materials in the future[124]. - The company aims to enhance operational efficiency and shareholder value through the acquisition of Hankan Pharmaceutical, which has a strong product line and R&D team[118]. - The company is in the process of issuing stocks to raise funds for the industrialization of its new drug CPT and the first phase of its raw material drug production base[77]. - The company has not proposed any cash dividend distribution plan for the reporting period despite having positive distributable profits[133].

2021-034 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 武汉海特生物制药股份有限公司 2021 年第一季度报告 2021 年 04 月 1 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证季度报告中财务报表的真实、准确、完整。 2 武汉海特生物制药股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 157,828,324.48 | 64,692,430.52 | 143.97% | | 归属于上市公司股东的净利润（元） ...

武汉海特生物制药股份有限公司 2020 年第三季度报告全文 武汉海特生物制药股份有限公司 2020 年第三季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈亚、主管会计工作负责人夏汉珍及会计机构负责人(会计主管 人员)羡雯声明：保证季度报告中财务报表的真实、准确、完整。 2020-071 2020 年 10 月 1 武汉海特生物制药股份有限公司 2020 年第三季度报告全文 2 武汉海特生物制药股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,128,227,648.15 | 2,169,508,822.12 | | -1.90% | | 归属于上市公司股东的净资 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥192,340,793.97, a decrease of 39.68% compared to ¥318,890,414.39 in the same period last year[21]. - The net profit attributable to shareholders was a loss of ¥3,779,622.28, representing a decline of 106.77% from a profit of ¥55,806,029.49 in the previous year[21]. - The net cash flow from operating activities was negative at ¥8,486,565.63, a significant drop of 198.31% compared to ¥8,632,837.83 in the same period last year[21]. - The basic earnings per share were -¥0.04, down 107.41% from ¥0.54 in the previous year[21]. - The company's revenue for the reporting period was ¥192,340,793.97, a decrease of 39.68% compared to ¥318,890,414.39 in the same period last year, primarily due to the impact of the pandemic and policy changes in the pharmaceutical industry[72]. - Operating costs increased by 89.40% to ¥74,073,597.75 from ¥39,109,087.21, mainly due to changes in the scope of consolidated financial statements[72]. - Research and development expenses rose by 29.36% to ¥34,819,321.54 from ¥26,916,753.77, reflecting the company's commitment to innovation[73]. - The company reported a total of CNY 67,606,730.40 in inventory as of June 30, 2020, up from CNY 56,582,644.27 at the end of 2019, indicating an increase of about 19.9%[162]. - The company reported a total of CNY 1,008,000 in profit distribution to shareholders[189]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,165,709,092.70, a slight decrease of 0.18% from ¥2,169,508,822.12 at the end of the previous year[21]. - The company's total assets amounted to CNY 2,165,709,092.70, a slight decrease from CNY 2,169,508,822.12 at the end of 2019[162]. - Total liabilities increased to CNY 426,116,592.98 from CNY 409,026,726.23, marking an increase of about 4.2%[164]. - The company's equity attributable to shareholders decreased to CNY 1,731,896,614.88 from CNY 1,752,293,190.99, a decrease of approximately 1.2%[165]. - The total liabilities at the end of the current period were 7,695 million yuan[186]. - The total owner's equity at the end of the current period was 1,725,411,200 CNY, a decrease of 31,303,440 CNY compared to the previous period[192]. Research and Development - The company is focused on the research, production, and sales of innovative biopharmaceuticals, including the injection of mouse nerve growth factor and anti-hepatitis transfer factor[28]. - The company has established a protein structure simulation platform to enhance the success rate of recombinant protein construction[29]. - The company is developing several small molecule generic drugs, including injection of Paracetamol sodium and injection of Esomeprazole sodium, with progress reported as smooth[29]. - The CPT project, a targeted gene-engineered anti-tumor new drug, has received multiple national project grants and is in advanced clinical trial stages[31]. - The company has a strong patent portfolio for CPT, with core patents authorized in 17 countries and regions[31]. - The company has established four major research platforms for drug formulation, including oral immediate release, oral controlled release, injection, and other related formulations[36]. - The company has a dedicated technical center that collaborates with institutions like Huazhong University of Science and Technology and Wuhan University to enhance new drug innovation projects[38]. - The company is actively expanding its product range and has initiated the development of new drugs while enhancing its research capabilities[29]. Market and Sales Strategy - The company primarily adopts a distribution model for sales, participating in centralized procurement tenders across provinces and selling products through licensed pharmaceutical distribution companies[45]. - The company has established a comprehensive market sales service system, enhancing its market planning and cultivation capabilities[60]. - The company established an online and offline marketing network, focusing on key disciplines such as neurosurgery and pediatrics, to adapt to market changes[70]. - The company has a strong market presence in neurology and oncology, with a nationwide sales service network and loyal customer base[61]. Corporate Governance and Compliance - The company will not distribute cash dividends or issue bonus shares for the reporting period[8]. - The company reported no significant litigation or arbitration matters during the reporting period[111]. - There were no penalties or rectification measures taken against the company during the reporting period[112]. - The company did not engage in any major related party transactions during the reporting period[114]. - The company has not undergone any changes in its board of directors, supervisors, or senior management during the reporting period[155]. Investment and Funding - The total amount of raised funds was RMB 797,475,854.40, after deducting fees[86]. - During the reporting period, RMB 499.74 million of the raised funds were invested[84]. - The project for upgrading the biological engineering drug comprehensive preparation base has an investment commitment of RMB 22,000 million, with 95.32% progress[88]. - The company has engaged in entrusted financial management with a total amount of 66,070 million CNY, with no overdue amounts reported[95]. - The company has provided entrusted loans totaling 10,350 million CNY to Beijing Shadong Biotechnology Co., Ltd., with interest rates ranging from 3.85% to 4.75%[97]. Social Responsibility - The company established a poverty alleviation subsidiary in Ying Shan County, investing CNY 22.25 million in agricultural poverty alleviation projects[130]. - The company plans to continue enhancing its poverty alleviation efforts by providing training for local farmers on the cultivation of Dendrobium[132].

Financial Performance - Total operating revenue for Q1 2020 was ¥64,692,430.52, a decrease of 58.61% compared to ¥156,308,732.68 in the same period last year[7] - Net profit attributable to shareholders was ¥4,250,575.75, down 85.76% from ¥29,854,699.68 year-on-year[7] - The net profit after deducting non-recurring gains and losses was -¥912,044.87, a decline of 103.47% compared to ¥26,295,585.08 in the previous year[7] - Basic and diluted earnings per share were both ¥0.04, down 86.21% from ¥0.29 in the previous year[7] - The weighted average return on net assets was 0.24%, down 1.50% from 1.74% year-on-year[7] - The company reported total revenue of ¥64,692,430.52, a decrease of 58.61% compared to the same period last year, primarily due to the impact of the pandemic and industry policy adjustments[20] - Net profit attributable to shareholders was ¥4,250,575.75, down 85.76% year-on-year, influenced by increased R&D expenses amid challenging market conditions[20] - The total operating revenue for Q1 2020 was CNY 35,661,736.10, a decrease from CNY 111,563,797.17 in the previous period[46] - The net profit for Q1 2020 was CNY 4,052,881.96, compared to CNY 29,274,813.57 in the same period last year, representing a decline of approximately 86.2%[43] - The operating profit for Q1 2020 was CNY 4,003,105.48, down from CNY 36,015,025.81 in the previous year, indicating a significant decrease of about 88.9%[43] - The total comprehensive income for Q1 2020 was CNY 4,052,881.96, down from CNY 29,274,813.57 in the previous year, indicating a decline of approximately 86.2%[44] Cash Flow and Investments - Net cash flow from operating activities was ¥5,040,127.69, a decrease of 72.36% from ¥18,232,746.92 in the same period last year[7] - Cash received from sales of goods and services decreased by 47.30% to ¥166,143,664.39, reflecting reduced sales and cash collection due to the pandemic[19] - The company’s cash flow from operating activities decreased by 66.13% to ¥92,070,227.12, attributed to business slowdown from the pandemic[19] - The cash inflow from operating activities was CNY 92,925,757.90, down from CNY 170,807,394.71 in the previous period[50] - The net cash flow from investing activities was -115,974,367.24 CNY, worsening from -27,553,949.36 CNY in the previous period[51] - Cash inflow from investment activities totaled 172,065,458.06 CNY, significantly higher than 4,874,236.90 CNY in the previous period[51] - The company reported a significant increase in cash inflow from investment recovery, totaling 105,000,000.00 CNY[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,172,082,531.55, an increase of 0.12% from ¥2,169,508,822.12 at the end of the previous year[7] - Net assets attributable to shareholders at the end of the reporting period were ¥1,755,902,038.39, up 0.21% from ¥1,752,293,190.99 at the end of the previous year[7] - Total current assets as of March 31, 2020, are 1,459,700,825.59[33] - Total liabilities were CNY 309,460,746.56, compared to CNY 302,863,570.22 in the previous period[39] - Owner's equity reached CNY 1,726,901,021.15, slightly increasing from CNY 1,723,307,270.63 in the previous period[39] - Long-term liabilities were recorded at CNY 7,539,362.48, suggesting manageable debt levels[61] - The total liabilities and owner's equity combined reached CNY 2,026,170,840.85, reflecting a balanced financial structure[61] Research and Development - The company is advancing the clinical trial for its CPT drug, which targets multiple myeloma, with plans for new drug registration and market launch[21] - Research and development expenses for Q1 2020 were CNY 10,613,763.54, slightly lower than CNY 10,996,448.47 in the previous period[42] Government Support and Shareholder Information - The company received government subsidies amounting to ¥881,091.81 during the reporting period[8] - The total number of ordinary shareholders at the end of the reporting period was 17,731[11] Investment Projects - The company increased its long-term equity investments to ¥5,000,000.00, marking a 100% increase due to new external investments[18] - The company’s intangible assets rose by 42.46% to ¥90,877,995.45, primarily due to the acquisition of land[18] - Investment payments surged by 3905.81% to ¥275,600,000.00, driven by new long-term investments and increased financial products purchases[19] - The total amount of committed investment projects is 79,747.59 million, with 42,979 million already invested[26] - The investment in the biological engineering drug comprehensive preparation base upgrade project is 22,000 million, with a progress rate of 21.03%[25] - The R&D center and laboratory construction project has a total investment of 38,030 million, with a completion rate of 141.24%[25] - The marketing service network upgrade project has an investment of 10,188 million, with a progress rate of 1.91%[25] Financial Reporting and Audit - The company has not undergone an audit for the first quarter report, which may affect investor confidence[63] - The company is implementing new revenue and leasing standards starting in 2020, which may impact future financial reporting[62]

Financial Performance - The company's operating revenue for 2019 was CNY 620,163,188.70, representing a 4.96% increase compared to CNY 590,873,499.47 in 2018[19] - The net profit attributable to shareholders decreased by 33.04% to CNY 63,035,065.41 from CNY 94,137,745.35 in the previous year[19] - The net profit after deducting non-recurring gains and losses was CNY 35,084,959.85, down 47.55% from CNY 66,887,868.43 in 2018[19] - The basic earnings per share fell by 32.97% to CNY 0.61 from CNY 0.91 in 2018[19] - The cash flow from operating activities was CNY 63,027,543.20, a decrease of 14.16% from CNY 73,423,479.40 in 2018[19] - The weighted average return on net assets was 3.65%, down from 5.45% in the previous year[19] - The total cost of sales for 2019 was ¥120,258,532.88, reflecting a 172.01% increase compared to the previous year[64] - The gross profit margin for the biopharmaceutical sector was 93.01%, down 1.78% from the previous year[63] - The biopharmaceutical sector generated ¥410,980,665.17 in revenue, a significant decline of 25.20% from ¥549,411,757.26 in 2018, accounting for 66.27% of total revenue[61] - Revenue from medical technology services surged by 547.64% to ¥168,046,745.77 from ¥25,947,563.02 in 2018, representing 27.10% of total revenue[61] Research and Development - The company plans to focus on innovative drug research and development in the coming years[6] - The company aims to enhance its molecular diagnostic technology platform and develop a series of molecular diagnostic products targeting various diseases[31] - The company has developed over 400 products, with 165 clinical approvals and 43 production approvals, including 26 new drug certificates, of which 3 are innovative drugs[46] - Research and development expenses increased by 109.83% to ¥62,649,772.71 from ¥29,857,003.83 in 2018, reflecting enhanced investment in R&D[71] - The number of R&D personnel increased to 190 in 2019, representing 24.93% of the total workforce, up from 13.20% in 2018[74] - R&D investment amounted to ¥62,649,772.71 in 2019, accounting for 10.10% of operating revenue, compared to 5.05% in 2018[74] Market Position and Strategy - The company aims to become the best innovative drug enterprise in China, focusing on biomedicine, small molecule CRO, CDMO, and high-end raw materials[40] - The company operates as a full-chain innovative biopharmaceutical enterprise, focusing on the research, development, production, and marketing of proprietary drugs[34] - The company is expanding its product categories by developing generic drugs such as injectable parecoxib sodium and acyclovir raw materials, with progress in small-scale process research[53] - The company is pursuing both organic growth and external expansion, establishing subsidiaries to enhance its raw material drug supply capabilities[57] - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[169] Governance and Compliance - The company has established a governance structure that includes a board of directors with 9 members, including 3 independent directors[182] - The company has maintained a high level of governance, with independent directors actively participating in board meetings and shareholder meetings, ensuring transparency and accountability[195] - The company has not engaged in any related party transactions that would harm the interests of non-related shareholders[187] - The company has implemented a strict external guarantee system, ensuring no guarantees are provided for the controlling shareholder or its affiliates[191] - The internal control evaluation report indicates that 100% of the total assets and operating income of the evaluated units are included in the company's consolidated financial statements[199] Social Responsibility - The company actively participates in social responsibility initiatives, such as poverty alleviation through agricultural projects, benefiting local farmers[188] - The company established a poverty alleviation industry self-company in Ying County, investing 79.53 million CNY to help 12 registered impoverished individuals escape poverty[134] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[169] - New product development includes the launch of a novel drug that is expected to enter the market by Q3 2024, with projected sales of 300 million yuan in the first year[169] - A strategic acquisition of a smaller biotech firm was announced, which is expected to enhance the company's R&D capabilities and add 150 million yuan in annual revenue[169] Employee Engagement and Development - In 2019, the company conducted various cultural activities to foster a strong corporate culture and employee engagement[58] - The company organized 12 sessions of "Haiter Ladder Lectures" in 2019, focusing on pharmaceutical industry knowledge and employee development[176] - The company adjusted the salary structure, increasing base salaries by 10%, 8%, and 5% based on performance evaluations[174] Cash Dividends - The company will distribute cash dividends of 1.6 yuan per 10 shares, totaling 16,536,806.40 yuan, based on a total share capital of 103,355,040 shares[101] - The total cash dividend for 2019 amounted to CNY 16,536,806.40, representing 26.23% of the net profit attributable to the company's ordinary shareholders[106] - The company has consistently maintained a cash dividend payout ratio above 20% over the past three years, in line with its profit distribution policy[106]

Financial Performance - Operating revenue for the reporting period was ¥151,632,930.06, representing a year-on-year increase of 5.69%[7] - Net profit attributable to shareholders of the listed company decreased by 58.26% to ¥12,322,764.52[7] - Basic earnings per share fell by 58.62% to ¥0.12[7] - Operating profit decreased to ¥11,277,718.58, down 64.9% from ¥32,145,845.96 in the previous period[34] - Net profit for the current period was ¥12,023,050.16, a decline of 58.7% compared to ¥29,094,656.33 in the previous period[35] - Net profit for the period was ¥66,885,959.58, a decrease of 10.4% from ¥74,525,283.06 in the same period last year[41] - The total profit for the period was ¥81,572,180.28, down from ¥85,878,097.01 in the same period last year[41] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,160,910,933.28, an increase of 0.26% compared to the end of the previous year[7] - Total liabilities increased, with accounts payable rising by 33.77% to CNY 18,498,428.13, reflecting the new consolidation scope[16] - Current liabilities decreased to CNY 379,383,859.44 from CNY 431,158,562.22, showing a reduction of approximately 12%[25] - The company’s total liabilities decreased to CNY 393,779,212.20 from CNY 445,771,822.49, a reduction of about 11.7%[25] - Total assets increased to CNY 2,160,910,933.28, up from CNY 2,155,356,658.35 in the previous period, reflecting a growth of approximately 0.26%[24] Cash Flow - Cash flow from operating activities for the year-to-date was ¥26,525,443.52, down 30.06%[7] - Total cash flow from operating activities was ¥513,141,581.29, compared to ¥460,307,943.23 in the previous period[48] - The net cash flow from operating activities for Q3 2019 was ¥26,525,443.52, a decrease of 30% compared to ¥37,926,248.99 in the same period last year[49] - The net cash flow from investment activities was ¥412,368,707.34, significantly higher than ¥72,427,713.63 in the previous year, marking a 470% increase[50] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 3.46% to ¥1,758,337,841.03[7] - The total number of ordinary shareholders at the end of the reporting period was 14,888[11] - The largest shareholder, Wuhan Sanjiangyuan Investment Development Co., Ltd., held 38.70% of the shares[11] Research and Development - R&D expenses increased by 126.86% to CNY 42,092,127.18, reflecting heightened investment in research and development[16] - Research and development expenses increased to ¥15,175,373.41, up 55.1% from ¥9,737,233.09 in the previous period[33] - Research and development expenses increased to ¥42,092,127.18, representing a 127.5% rise from ¥18,554,447.32 in the previous period[39] Financial Adjustments and Standards - The company reported a credit impairment loss of -¥6,023,423.50, reflecting challenges in asset management compared to the previous period[34] - The implementation of the new financial instrument standards led to an adjustment that increased shareholder equity by CNY 10,128,424.60, with an increase in retained earnings of the same amount[68] - The financial report reflects compliance with the new financial instrument standards effective from January 1, 2019[64] Other Income and Expenses - Other income grew by 178.19% to CNY 2,678,754.33, driven by government subsidies and expanded consolidation scope[16] - Investment income decreased to ¥5,923,641.93, down 51.2% from ¥12,144,044.86 in the previous period[33] - Financial expenses showed a net income of -¥3,618,732.28, compared to -¥1,773,484.13 in the previous period, indicating improved financial management[33]

Financial Performance - Total operating revenue for the first half of 2019 was CNY 318,890,414.39, representing an increase of 18.73% compared to CNY 268,582,253.82 in the same period last year[24]. - Net profit attributable to shareholders was CNY 55,806,029.49, up 20.10% from CNY 46,465,576.47 year-on-year[24]. - Net profit after deducting non-recurring gains and losses reached CNY 39,793,269.55, a significant increase of 48.98% compared to CNY 26,710,462.09 in the previous year[24]. - Basic earnings per share rose to CNY 0.54, reflecting a growth of 20.00% from CNY 0.45 in the same period last year[24]. - The company reported a total non-operating income of CNY 16,012,759.94 for the reporting period[28]. - The company achieved operating revenue of CNY 318,890,414.39, representing a year-on-year growth of 18.73%[40]. - The net profit attributable to shareholders was CNY 55,806,029.49, with a year-on-year increase of 20.10%[40]. - Research and development expenses rose to CNY 26,916,753.77, marking a significant increase of 210.99% compared to the previous period[44]. - The company reported a significant increase in prepayments, rising to ¥42,732,528.18 from ¥4,184,143.95, indicating a growth of over 920%[123]. - The total comprehensive income for the period was 29.4 million, reflecting a decrease of 943 thousand compared to the previous period[151]. Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 8,632,837.83, a decrease of 73.84% compared to CNY 32,997,755.46 in the previous year[24]. - The company’s cash and cash equivalents increased by 2,521.95% to CNY 187,633,446.42, primarily due to increased cash inflows from investments[44]. - The total cash and cash equivalents at the end of the period stood at ¥494,703,481.19, down from ¥704,738,521.61 at the end of the first half of 2018[144]. - The company received cash of ¥246,000,000.00 from other investment activities, a substantial increase from ¥34,000,000.00 in the same period last year[144]. - The total amount of other assets at the end of the period was RMB 294 million, sourced from raised funds[52]. - The total assets at the end of the reporting period were CNY 2,142,247,897.96, a slight decrease of 0.61% from CNY 2,155,356,658.35 at the end of the previous year[24]. - The company’s total assets at the end of the reporting period were 1,725.41 million yuan, with a notable increase in cash and cash equivalents[162]. Product and Market Focus - The company faces significant reliance on its main product, injectable mouse nerve growth factor, which constitutes a major portion of its revenue[7]. - The company plans to focus on the research and development of innovative biological drugs in the coming years[10]. - The main product was removed from the National Basic Medical Insurance Drug List, which may adversely affect sales starting January 1, 2020[9]. - The company operates in the biopharmaceutical sector, which has high technical barriers and profit margins, with a growing market demand for biological drugs[34]. - The market for biopharmaceuticals is expected to continue expanding, driven by an aging population and increasing healthcare needs[34]. - The company is focusing on enhancing its R&D capabilities to introduce innovative products in the biopharmaceutical sector[158]. - The company plans to expand its market presence through new product development and strategic partnerships in the upcoming quarters[151]. Investments and Subsidiaries - The company’s subsidiaries focus on various diagnostic reagents and small molecule drug services, enhancing its product portfolio[33]. - The company reported a total investment of 36,768 million CNY for the acquisition of Hankan Pharmaceutical, with an actual investment of 25,300 million CNY, achieving a progress rate of 68.81%[60]. - The company has established a subsidiary for poverty alleviation in Ying Shan County, investing a total of 69.33 million yuan in various poverty alleviation projects[93]. - The wholly-owned subsidiary Hanrui Pharmaceutical (Jingmen) Co., Ltd. has completed its business registration and obtained a business license from the Jingmen Administration for Industry and Commerce[98]. - The controlling subsidiary Tianjin Hanrui Pharmaceutical Co., Ltd. received the drug registration approval for Ondansetron Injection from the National Medical Products Administration, with approval number 2018S00680[98]. Risk and Compliance - The company is committed to optimizing its internal control management to improve overall operational efficiency[41]. - The company has not encountered any major changes in the feasibility of its projects[60]. - The company has not reported any issues or questions regarding the use and disclosure of raised funds[58]. - The company has not faced any major litigation or arbitration matters during the reporting period[79]. - The company has not engaged in any significant related party transactions during the reporting period[82]. Shareholder and Governance - The total number of ordinary shareholders at the end of the reporting period was 14,857[106]. - The company’s limited shares increased by 105,075 shares during the reporting period, primarily due to executive lock-up shares[104]. - The total number of shares remained unchanged at 103,355,040 shares[102]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[109]. - The company’s board of directors saw a change with the resignation of the deputy general manager due to retirement[116]. Accounting and Financial Reporting - The financial report for the first half of 2019 was not audited[121]. - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect its financial position and operating results[171]. - The company uses Renminbi as its functional currency for accounting purposes[174]. - The group employs the equity method for accounting treatment in business combinations under common control[175]. - The company recognizes expected credit losses for financial instruments classified as amortized cost and those measured at fair value with changes recognized in other comprehensive income[189].

证券代码：300683 证券简称：海特生物 公告编号：2019-031 武汉海特生物制药股份有限公司 关于参加湖北辖区上市公司2019年度投资者网上集体接待日 活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 召开时间：2019年6月13日（星期四）15:10-16:50。 召开方式：网络在线交流方式。 一、说明会情况 为便于广大投资者更深入全面地了解公司情况，公司决定以网络在线交流方 式参加湖北证监局、湖北省上市公司协会、深圳市全景网络有限公司联合举办的 湖北辖区上市公司2019年度投资者网上集体接待日活动。公司将积极参与活动并 围绕2018年年度报告、经营状况、发展战略、公司治理等投资者所关心的问题， 通过互动平台与投资者进行"一对多"形式的沟通交流。 二、说明会召开时间 本次说明会召开时间为 2019 年 6 月 13 日 15:10-16:50。 三、参加人员 公司出席本次年度网上说明会的人员有公司副总经理、董事会秘书陈煌先 生，财务总监夏汉珍女士。 四、投资者参加方式 本次说明会将通过网上平台采取网络远程的方式举行，投资者可 ...

Financial Performance - The company's operating revenue for 2018 was ¥590,873,499.47, a decrease of 21.24% compared to ¥750,258,800.06 in 2017[19] - The net profit attributable to shareholders for 2018 was ¥94,137,745.35, down 33.89% from ¥142,389,649.91 in 2017[19] - The net profit after deducting non-recurring gains and losses was ¥66,887,868.43, a decline of 46.30% compared to ¥124,548,584.96 in 2017[19] - The basic earnings per share for 2018 was ¥0.910, a decrease of 44.85% from ¥1.650 in 2017[19] - The company achieved operating revenue of CNY 590,873,499.48 and net profit of CNY 91,464,026.87 in 2018[30] - The company achieved an annual revenue of ¥590 million, a decrease of 21.3% year-on-year, and a net profit attributable to shareholders of ¥94 million, down 33.8% year-on-year[41] - Revenue from the pharmaceutical manufacturing industry was ¥579,442,124.16, down 22.29% from ¥745,626,445.36 in 2017[50] - The gross profit margin for the pharmaceutical manufacturing industry was 92.54%, a decrease of 3.03% from the previous year[50] Assets and Liabilities - The total assets at the end of 2018 were ¥2,155,356,658.35, an increase of 12.92% from ¥1,908,751,901.97 at the end of 2017[19] - The net assets attributable to shareholders at the end of 2018 were ¥1,699,551,638.99, up 3.86% from ¥1,636,420,405.64 at the end of 2017[19] - The company's fixed assets increased by ¥89,004,480.56, a growth of 90.36%, primarily due to the inclusion of Zhuhai Hi-Tech Biopharmaceutical Co., Ltd. and Tianjin Hankan Pharmaceutical Biotechnology Co., Ltd. in the consolidation scope[36] - Intangible assets rose by ¥47,917,556.54, reflecting a significant increase of 263.42%, also due to the consolidation of the aforementioned companies[36] - Construction in progress increased by ¥26,405,708.95, marking a 307.64% rise, attributed to increased project investments during the reporting period[36] - Goodwill increased by ¥275,398,382.15, resulting from the acquisition of Zhuhai Hi-Tech Biopharmaceutical Co., Ltd. and Tianjin Hankan Pharmaceutical Biotechnology Co., Ltd.[36] Research and Development - The company plans to focus on the research and development of biological innovative drugs in the coming years[6] - The company is advancing its research projects, including the recombinant human nerve growth factor project, with a target protein yield exceeding 40 mg/L and purity above 98%[42] - Research and development expenses amounted to ¥29,857,003.83, representing 5.05% of total revenue, with a year-on-year increase of 21.88%[60] - R&D investment amounted to ¥29,857,003.83, representing 5.05% of operating revenue, a significant increase from 3.27% in 2017[61] - The company aims to enhance its innovation capabilities in large molecule drugs, small molecule drugs, and in vitro diagnostics[81] - The company has completed the R&D center and laboratory construction project but cannot account for its individual economic benefits[72] Market and Competition - The global pharmaceutical market exceeded USD 1.1 trillion in 2018, with a five-year compound annual growth rate of 5.65%[32] - The biopharmaceutical industry has high technical barriers and profit margins, making it one of the fastest-growing sectors in the pharmaceutical industry[33] - The company's main product competes with three other companies in a market characterized by oligopoly[34] - The biopharmaceutical market is expected to grow as more biopharmaceuticals are included in the medical insurance directory, increasing market demand[33] Acquisitions and Expansion - The company acquired Zhuhai Economic Special Zone Haitai Biopharmaceutical Co., Ltd. in March 2018, entering the in vitro diagnostic reagent field[31] - In October 2018, the company acquired Tianjin Hankan Pharmaceutical Biotechnology Co., Ltd., which provides a full industry chain for small molecule drug research and development[32] - The company completed the acquisition of Tianjin Hankan, enhancing its research and development capabilities and reducing reliance on single products[45] - The company plans to expand its product line and reduce reliance on a single product, particularly the injection of nerve growth factor, which currently constitutes a significant portion of revenue[81] Cash Flow and Financial Management - The company has experienced a decline in cash flow from operating activities, which was ¥73,423,479.40 in 2018, down 11.62% from ¥83,076,511.58 in 2017[19] - Operating cash inflow decreased by 12.61% to ¥680,206,581.72, while operating cash outflow decreased by 12.73% to ¥606,783,102.32, resulting in a net cash flow of ¥73,423,479.40, down 11.62%[61] - Investment cash inflow plummeted by 91.15% to ¥69,064,976.56, primarily due to a reduction in the recovery of maturing financial products[61] - Financing cash inflow dropped by 99.25% to ¥6,000,000.00, mainly due to the previous year's fundraising activities[61] - Total cash and cash equivalents decreased by 535.85% to -¥390,512,218.72, indicating a significant cash outflow[61] - The proportion of monetary funds to total assets decreased by 22.30%, from 36.55% in 2017 to 14.25% in 2018[67] Shareholder Information - The proposed cash dividend is CNY 2.00 per 10 shares, totaling CNY 20,671,008.00, which represents 21.96% of the net profit attributable to ordinary shareholders[94] - The total number of shares for the dividend distribution is 103,355,040 shares[90] - The company has a clear profit distribution policy that complies with legal regulations and has a complete decision-making process[89] - The company has not issued any bonus shares or conducted capital reserve transfers during the reporting period[90] - The total number of shares before the change was 103,355,000, with a post-change total of 103,355,000, indicating no overall change in total shares[133] Governance and Compliance - The company has established a governance structure compliant with relevant laws, including a complete set of regulations such as the Articles of Association and rules for shareholder meetings[168] - The board of directors consists of 9 members, including 3 independent directors, and has established specialized committees for audit, compensation, strategy, and nomination[170] - The independent directors have not raised any objections regarding company matters during the reporting period, indicating a consensus on governance[185] - The audit committee has effectively implemented the internal audit system and facilitated communication between internal and external audits[187] - The company has not identified any significant internal control deficiencies during the reporting period, reflecting strong internal governance[191] Social Responsibility - The company actively engages in social responsibility initiatives, including poverty alleviation projects that provide employment opportunities and agricultural support to local farmers[177] - The company established a poverty alleviation industry company, investing 116.04 million CNY in poverty alleviation efforts, helping 33 registered impoverished individuals to escape poverty[125] - The company plans to continue enhancing poverty alleviation efforts by providing employment opportunities and training in the cultivation of Dendrobium[127] Employee Information - The total number of employees in the company is 659, with 294 in the parent company and 365 in major subsidiaries[163] - The company has 8 employees with a doctoral degree, 100 with a master's degree, and 315 with a bachelor's degree[163] - The total remuneration for directors and senior management during the reporting period amounts to 275.26 million yuan[162] - The highest remuneration is received by the chairman and general manager, Chen Ya, at 58.26 million yuan[161] - In 2018, nearly 90% of employees received a salary increase, with an additional 20% of outstanding employees receiving extra adjustments in both base salary and allowances[164] Internal Control and Audit - Wuhan Haitai Biopharmaceutical Co., Ltd. maintained effective internal control related to financial statements as of December 31, 2018[193] - The company reported zero significant defects in both financial and non-financial reports for the year 2018[194] - The audit opinion issued by Zhongzheng Zhonghuan Accounting Firm was a standard unqualified opinion, confirming the fair presentation of the financial statements[198] - The internal control audit report was disclosed on April 19, 2019, confirming no major defects in non-financial reporting[194]